1779 – Testing of tumour tissue to detect FGFR2 fusions or rearrangements in people with cholangiocarcinoma, to determine eligibility for treatment with PBS subsidised futibatinib

Page last updated: 31 May 2024

Application Detail

Description of Medical Service

The test is to detect fusions or rearrangements in the FGFR2 gene in tumour tissue. Testing may be performed using next generation sequencing (NGS) or fluorescence in situ hybridisation (FISH). This test is for patients with locally advanced or metastatic cholangiocarcinoma and is used to determine eligibility for a potential new PBS subsidised treatment, futibatinib.

Description of Medical Condition

Cholangiocarcinoma is a rare type of cancer that develops in the bile ducts. The bile ducts are a group of thin tubes that carry bile (a digestive fluid) from the liver and gallbladder to the intestines.

Reason for Application

New MBS item (MSAC-PBAC co-dependent submission)

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 149 KB)
Application Summary (Word 28 KB)

Application PICO Set (PDF 353 KB)
Application PICO Set (Word 108 KB)

Consultation Survey

Consultation Survey

PASC Consultation
PASC consultation closes Friday 12 July 2024. Any consultation received after this date will automatically be included in the MSAC consultation for this application.

MSAC Consultation
MSAC consultation TBA – please subscribe to the MSAC email bulletin to be notified when this application is scheduled for MSAC consideration. The bulletin will also advise the closing date for consultation input.

For further information please refer to PASC, ESC, MSAC Key Dates

For further information on the consultation proves please refer to MSAC Consultation Process

PICO Confirmation


Assessment Report


Public Summary Document


Meetings for this Application


15-16 August 2024